Neurotech International (ASX:NTI) - Prezzo delle azioni, notizie e analisi

NTI Panoramica delle azioni

NTI analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 44.67% all'anno

Analisi del rischio

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Non ha entrate significative ( A$3M )

Non ha una capitalizzazione di mercato significativa ( A$63M )

Neurotech International Limited Concorrenti

CurveBeam AI

ASX:CVB

AU$41.4m

Micro-X

ASX:MX1

AU$39.0m

CardieX

ASX:CDX

AU$35.3m

SomnoMed

ASX:SOM

AU$60.5m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Neurotech International
Prezzi storici delle azioni
Prezzo attuale dell'azione	AU$0.066
Massimo di 52 settimane	AU$0.13
Minimo di 52 settimane	AU$0.048
Beta	1.48
1Variazione di 1 mese	29.41%
Variazione a 3 mesi	-8.33%
Variazione di 1 anno	15.79%
3Variazione a 3 anni	3.13%
Variazione a 5 anni	266.67%
Variazione dall'IPO	-76.84%

Notizie e aggiornamenti recenti

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Nov 19

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 19

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Jan 28

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Oct 14

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Jul 01

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Jan 21

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Oct 06

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

May 18

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Dec 21

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Sep 04

Need To Know: Neurotech International Limited (ASX:NTI) Insiders Have Been Selling Shares

Dec 08

Rendimenti per gli azionisti

	NTI	AU Medical Equipment	AU Mercato
7D	22.2%	0.6%	1.4%
1Y	15.8%	15.3%	17.7%

Ritorno vs Industria: NTI ha trovato corrispondenza nel Australian Medical Equipment che ha restituito 15.3 % nell'ultimo anno.

Rendimento vs Mercato: NTI ha avuto una performance inferiore al mercato Australian che ha registrato un rendimento 17.7 % nell'ultimo anno.

Volatilità dei prezzi

Is NTI's price volatile compared to industry and market?
NTI volatility
NTI Average Weekly Movement	8.7%
Medical Equipment Industry Average Movement	9.0%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Prezzo delle azioni stabile: NTI non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di NTI è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2016	n/a	Peter James Griffiths	www.neurotechinternational.com

Neurotech International Limited, società di sviluppo biofarmaceutico in fase clinica, si occupa di ricerca, progettazione, sviluppo e produzione di dispositivi e soluzioni mediche in Australia. L'azienda si concentra sullo sviluppo e sulla commercializzazione di NTI164 per molteplici disturbi neurologici pediatrici e di Mente, una terapia domiciliare clinicamente testata per migliorare il coinvolgimento e il rilassamento dei bambini autistici che presentano un'elevata attività cerebrale in banda delta. L'azienda è inoltre impegnata nella realizzazione di progetti di ricerca medica e nello sviluppo di dispositivi tecnologici.

Neurotech International Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Neurotech International con la sua capitalizzazione di mercato?
NTI statistiche fondamentali
Capitalizzazione di mercato	AU$63.11m
Guadagni(TTM)	-AU$5.07m
Ricavi(TTM)	AU$3.18m

21.5x

Rapporto P/S

-13.5x

Rapporto P/E

NTI è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NTI Conto economico (TTM)
Ricavi	AU$3.18m
Costo del fatturato	AU$7.83k
Profitto lordo	AU$3.17m
Altre spese	AU$8.24m
Guadagni	-AU$5.07m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.0049
Margine lordo	99.75%
Margine di profitto netto	-159.54%
Rapporto debito/patrimonio netto	0%

Come si è comportato NTI nel lungo periodo?

Vedi performance storica e confronto

NTI Panoramica delle azioni

Premi

Analisi del rischio

Neurotech International Limited Concorrenti

ASX:CVB

AU$41.4m

ASX:MX1

AU$39.0m

ASX:CDX

AU$35.3m

ASX:SOM

AU$60.5m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Why Neurotech International Limited (ASX:NTI) Could Be Worth Watching

Now 21% overvalued

Now 20% overvalued

Neurotech International Limited, Annual General Meeting, Nov 20, 2024

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 10 million.

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Independent Non-Executive Director exercised options to buy AU$114k worth of stock.

Neurotech International Limited to Report Q1, 2024 Results on Oct 27, 2023

Neurotech International Limited, Annual General Meeting, Nov 15, 2023

We Think Neurotech International (ASX:NTI) Needs To Drive Business Growth Carefully

Full year 2023 earnings released: AU$0.01 loss per share (vs AU$0.005 loss in FY 2022)

New minor risk - Financial data availability

Neurotech International Limited to Report Q4, 2023 Results on Jul 26, 2023

New minor risk - Share price stability

Here's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

First half 2023 earnings released: AU$0.48 loss per share (vs AU$0.003 loss in 1H 2022)

Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial

Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension

Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial

Neurotech International Limited to Report Q3, 2023 Results on Jan 30, 2023

Is Neurotech International (ASX:NTI) In A Good Position To Invest In Growth?

Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD

Neurotech International Limited Announces Passing of Professor Allan Cripps AO, Non-Executive Director

Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder

Less than half of directors are independent

Neurotech International Limited, Annual General Meeting, Nov 30, 2022

Neurotech International Limited, Annual General Meeting, Nov 23, 2022

Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164

Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS

Is Neurotech International (ASX:NTI) In A Good Position To Deliver On Growth Plans?

Neurotech International Limited Provides Autism Spectrum Disorder Phase I/II Clinical Trial Update

Less than half of directors are independent

Neurotech International Limited Announces Transition of Alexandra Andrews from Chief Executive Officer to a New Position of Chief Operating Officer

Full year 2022 earnings released: AU$0.005 loss per share (vs AU$0.015 loss in FY 2021)

Neurotech International Limited Announces Currently Finalising a Pivotal Phase II/III Clinical Trial Design to be Conducted in Australia

Neurotech International ORDINARY FULLY PAID to Be Deleted from OTC Equity

Neurotech International Limited Announces Executive Changes

Neurotech International Limited Announces Results with NTI164 in Paediatric ASD

High number of new directors

Here's Why We're Watching Neurotech International's (ASX:NTI) Cash Burn Situation

Neurotech International Limited Announces Important Developments Relating to the Study Protocol Assessing NTI164 in Children with Autism Spectrum Disorder

High number of new directors

Neurotech International Limited Announces Successful Developments Relating to Safety and Tolerability of NTI164 and Key Behavioural Parameters That Impact Autism Spectrum Disorder Patients

Neurotech International Limited Appoints Alexandra Andrews as Chief Executive Officer, Effective 8 March 2022

We're Not Very Worried About Neurotech International's (ASX:NTI) Cash Burn Rate

Neurotech International Limited Announces Nti164 Clinical Program Update

Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

Full year 2021 earnings released: AU$0.015 loss per share (vs AU$0.011 loss in FY 2020)

Neurotech International Limited Announces the Continuation of Its Pre-Clinical Program in Neuro-Inflammatory Disease Models In-Line with Research and Development Pathway

Neurotech International Limited Initiates Phase I/II Open Label Study into Autism

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2 million.

Neurotech International Limited Announces Strategic Cultivation Partnership with CannaPacific Limited

Neurotech International Limited Announces the Expansion of Its Exclusive License with Dolce Cann Global Pty Ltd

Neurotech International Limited Provides an Update on Clinical Study Program

Neurotech International Limited has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.